Department of Neurosurgery, Hyogo College of Medicine, 1-1 Mukogawacho, Nishinomiya, Hyogo 663-8501, Japan.
Department of Surgical Pathology, Hyogo College of Medicine, 1-1 Mukogawacho, Nishinomiya, Hyogo 663-8501, Japan.
Cells. 2020 Jun 1;9(6):1374. doi: 10.3390/cells9061374.
Ischemic stroke is a critical disease caused by cerebral artery occlusion in the central nervous system (CNS). Recent therapeutic advances, such as neuroendovascular intervention and thrombolytic therapy, have allowed recanalization of occluded brain arteries in an increasing number of stroke patients. Although previous studies have focused on rescuing neural cells that still survive despite decreased blood flow, expanding the therapeutic time window may allow more patients to undergo reperfusion in the near future, even after lethal ischemia, which is characterized by death of mature neural cells, such as neurons and glia. However, it remains unclear whether early reperfusion following lethal ischemia results in positive outcomes. The present study used two ischemic mouse models-90-min transient middle cerebral artery occlusion (t-MCAO) paired with reperfusion to induce lethal ischemia and permanent middle cerebral artery occlusion (p-MCAO)-to investigate the effect of early reperfusion up to 8 w following MCAO. Although early reperfusion following 90-min t-MCAO did not rescue mature neural cells, it preserved the vascular cells within the ischemic areas at 1 d following 90-min t-MCAO compared to that following p-MCAO. In addition, early reperfusion facilitated the healing processes, including not only vascular but also neural repair, during acute and chronic periods and improved recovery. Furthermore, compared with p-MCAO, early reperfusion after t-MCAO prevented behavioral symptoms of neurological deficits without increasing negative complications, including hemorrhagic transformation and mortality. These results indicate that early reperfusion provides beneficial effects presumably via cytoprotective and regenerative mechanisms in the CNS, suggesting that it may be useful for stroke patients that experienced lethal ischemia.
缺血性中风是一种由中枢神经系统 (CNS) 中脑动脉闭塞引起的危急疾病。最近的治疗进展,如神经血管介入和溶栓治疗,使得越来越多的中风患者的闭塞脑动脉得以再通。尽管以前的研究集中在拯救尽管血流减少但仍存活的神经细胞,但扩大治疗时间窗可能会使更多的患者在不久的将来接受再灌注治疗,即使在致命性缺血后,这一阶段以成熟神经细胞(如神经元和神经胶质)死亡为特征。然而,目前尚不清楚致命性缺血后早期再灌注是否会产生积极的结果。本研究使用了两种缺血性小鼠模型——90 分钟短暂性大脑中动脉闭塞(t-MCAO)配对再灌注以诱导致命性缺血和永久性大脑中动脉闭塞(p-MCAO)——来研究 MCAO 后长达 8 周的早期再灌注的效果。尽管 90 分钟 t-MCAO 后的早期再灌注不能挽救成熟的神经细胞,但与 p-MCAO 相比,它在 90 分钟 t-MCAO 后 1 天内保留了缺血区域内的血管细胞。此外,早期再灌注促进了急性和慢性期间的愈合过程,不仅包括血管修复,还包括神经修复,并改善了恢复情况。此外,与 p-MCAO 相比,t-MCAO 后的早期再灌注可预防神经功能缺损的行为症状,而不会增加包括出血性转化和死亡率在内的负面并发症。这些结果表明,早期再灌注通过中枢神经系统中的细胞保护和再生机制提供有益效果,表明它可能对经历致命性缺血的中风患者有用。